Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab versus zoledronic acid after screw fixation for osteoporotic vertebral compression fractures
ChiCTR2100051424Phase 4Not yet recruiting
- Sponsor
- Shenzhen People's Hospital
- Start
- Sep 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of denosumab and zoledronic acid in vertebral compression fracture (VCF) and osteoporosis (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoints: Osteocalcin N-terminal molecular fragment, Procollagen type 1 N-terminal propeptide (P1NP) and 19 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
denosumabzoledronic acid
03
Conditions
vertebral compression fracture (VCF)osteoporosis
Beyond the preview
Go deeper on ChiCTR2100051424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051424.